<DOC>
	<DOC>NCT00192647</DOC>
	<brief_summary>This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to standard-dose treatment, in treatment-naive participants with CHC, genotype 1 infection.</brief_summary>
	<brief_title>A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Diagnosis of chronic CHC, genotype 1 Chronic liver disease consistent with CHC on a biopsy sample obtained within the previous 36 months as judged by a local pathologist (all countries except Australia) Infection with Hepatitis C virus (Australian sites only had to meet Section 100 criteria for treatment with PEGIFN alfa2a plus ribavirin) Compensated liver disease Naive to interferonbased therapy for CHC infection Systemic antiviral, antineoplastic, or immunomodulatory treatment within 6 months of study drug Coinfection with active hepatitis A or B virus, or with human immunodeficiency virus (HIV) Chronic liver disease other than CHC infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>